دورية أكاديمية
Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study.
| العنوان: | Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study. |
|---|---|
| المؤلفون: | Harmsen MG; Department of Obstetrics & Gynaecology, Radboud University Medical Center, PO Box 9101, , 6500 HB, Nijmegen, The Netherlands. Marline.Harmsen@radboudumc.nl., Arts-de Jong M; Department of Obstetrics & Gynaecology, Radboud University Medical Center, PO Box 9101, , 6500 HB, Nijmegen, The Netherlands. Marieke.Arts-deJong@radboudumc.nl., Hoogerbrugge N; Department of Human Genetics, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands. Nicoline.Hoogerbrugge@radboudumc.nl., Maas AH; Department of Cardiology, Radboud University Medical Center, PO Box 9101, , 6500 HB, Nijmegen, The Netherlands. Angela.Maas@radboudumc.nl., Prins JB; Department of Medical Psychology, Radboud University Medical Center, PO Box 9101, , 6500 HB, Nijmegen, The Netherlands. Judith.Prins@radboudumc.nl., Bulten J; Department of Pathology, Radboud University Medical Center, PO Box 9101, , 6500 HB, Nijmegen, The Netherlands. Hans.Bulten@radboudumc.nl., Teerenstra S; Department for Health Evidence, Radboud University Medical Center, PO Box 9101, , 6500 HB, Nijmegen, The Netherlands. Steven.Teerenstra@radboudumc.nl., Adang EM; Department for Health Evidence, Radboud University Medical Center, PO Box 9101, , 6500 HB, Nijmegen, The Netherlands. Eddy.Adang@radboudumc.nl., Piek JM; Gynaecologic Oncologic Center South location Elisabeth-TweeSteden Hospital, Dr. Deelenlaan 5, 5042 AD, Tilburg, The Netherlands. Jurgen.Piek@catharinaziekenhuis.nl.; Catharina Hospital, Michelangelolaan 2, 5623 EJ, Eindhoven, The Netherlands. Jurgen.Piek@catharinaziekenhuis.nl., van Doorn HC; Department of Gynaecology, Erasmus MC Cancer Clinic, 's-Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands. H.vanDoorn@erasmusmc.nl., van Beurden M; Center for Gynaecological Oncology Amsterdam (CGOA), Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. M.v.Beurden@nki.nl., Mourits MJ; Department of Gynaecology, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands. M.J.E.Mourits@umcg.nl., Zweemer RP; Department of Gynaecological Oncology, UMC Utrecht Cancer Centre, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands. R.Zweemer@umcutrecht.nl., Gaarenstroom KN; Department of Obstetrics and Gynaecology, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands. K.N.Gaarenstroom@lumc.nl., Slangen BF; Department of Obstetrics and Gynaecology, Maastricht University Medical Centre, P. Debyelaan 25, 6229 HX, Maastricht, The Netherlands. Brigitte.Slangen@mumc.nl., Vos MC; Gynaecologic Oncologic Center South, Elisabeth-TweeSteden Hospital, Hilvarenbeekseweg 60, 5022 GC, Tilburg, The Netherlands. C.Vos@elisabeth.nl., van Lonkhuijzen LR; Center for Gynaecological Oncology Amsterdam (CGOA), AMC, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. L.R.vanLonkhuijzen@amc.uva.nl., Massuger LF; Department of Obstetrics & Gynaecology, Radboud University Medical Center, PO Box 9101, , 6500 HB, Nijmegen, The Netherlands. Leon.Massuger@radboudumc.nl., Hermens RP; Scientific Institute for Quality of Healthcare, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands. Rosella.Hermens@radboudumc.nl., de Hullu JA; Department of Obstetrics & Gynaecology, Radboud University Medical Center, PO Box 9101, , 6500 HB, Nijmegen, The Netherlands. Joanne.deHullu@radboudumc.nl. |
| المصدر: | BMC cancer [BMC Cancer] 2015 Aug 19; Vol. 15, pp. 593. Date of Electronic Publication: 2015 Aug 19. |
| نوع المنشور: | Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: London : BioMed Central, [2001- |
| مواضيع طبية MeSH: | BRCA1 Protein/*genetics , BRCA2 Protein/*genetics , Cystadenocarcinoma, Serous/*prevention & control , Menopause, Premature/*psychology , Ovarian Neoplasms/*prevention & control , Salpingectomy/*methods, Adult ; Cystadenocarcinoma, Serous/epidemiology ; Cystadenocarcinoma, Serous/genetics ; Female ; Genetic Predisposition to Disease ; Humans ; Incidence ; Middle Aged ; Mutation ; Ovarian Neoplasms/epidemiology ; Ovarian Neoplasms/genetics ; Ovariectomy/adverse effects ; Ovariectomy/economics ; Ovariectomy/methods ; Quality of Life ; Salpingectomy/adverse effects ; Salpingectomy/economics |
| مستخلص: | Background: Risk-reducing salpingo-oophorectomy (RRSO) around the age of 40 is currently recommended to BRCA1/2 mutation carriers. This procedure decreases the elevated ovarian cancer risk by 80-96% but it initiates premature menopause as well. The latter is associated with short-term and long-term morbidity, potentially affecting quality of life (QoL). Based on recent insights into the Fallopian tube as possible site of origin of serous ovarian carcinomas, an alternative preventive strategy has been put forward: early risk-reducing salpingectomy (RRS) and delayed oophorectomy (RRO). However, efficacy and safety of this alternative strategy have to be investigated. Methods: A multicentre non-randomised trial in 11 Dutch centres for hereditary cancer will be conducted. Eligible patients are premenopausal BRCA1/2 mutation carriers after completing childbearing without (a history of) ovarian carcinoma. Participants choose between standard RRSO at age 35-40 (BRCA1) or 40-45 (BRCA2) and the alternative strategy (RRS upon completion of childbearing and RRO at age 40-45 (BRCA1) or 45-50 (BRCA2)). Women who opt for RRS but do not want to postpone RRO beyond the currently recommended age are included as well. Primary outcome measure is menopause-related QoL. Secondary outcome measures are ovarian/breast cancer incidence, surgery-related morbidity, histopathology, cardiovascular risk factors and diseases, and cost-effectiveness. Mixed model data analysis will be performed. Discussion: The exact role of the Fallopian tube in ovarian carcinogenesis is still unclear. It is not expected that further fundamental research will elucidate this role in the near future. Therefore, this clinical trial is essential to investigate RRS with delayed RRO as alternative risk-reducing strategy in order to improve QoL. Trial Registration: ClinicalTrials.gov ( NCT02321228 ). |
| References: | J Sex Marital Ther. 2006 Jul-Sep;32(4):289-304. (PMID: 16709550) JAMA. 2006 Jul 12;296(2):185-92. (PMID: 16835424) J Clin Oncol. 2006 Aug 1;24(22):3576-82. (PMID: 16877724) Curr Opin Obstet Gynecol. 2007 Feb;19(1):3-9. (PMID: 17218844) Am J Surg Pathol. 2007 Feb;31(2):161-9. (PMID: 17255760) J Clin Oncol. 2007 Apr 10;25(11):1329-33. (PMID: 17416853) Br J Cancer. 2007 May 7;96(9):1335-42. (PMID: 17426707) J Clin Oncol. 2007 Sep 1;25(25):3985-90. (PMID: 17761984) J Clin Oncol. 2008 Mar 10;26(8):1331-7. (PMID: 18268356) Clin Cancer Res. 2008 Jul 1;14(13):4067-78. (PMID: 18593983) Menopause Int. 2008 Sep;14(3):111-6. (PMID: 18714076) Crit Rev Oncol Hematol. 2009 Jan;69(1):28-44. (PMID: 18656380) J Natl Cancer Inst. 2009 Jan 21;101(2):80-7. (PMID: 19141781) Am J Surg Pathol. 2009 Mar;33(3):376-83. (PMID: 19011565) Am J Surg Pathol. 2009 Aug;33(8):1125-36. (PMID: 19440148) Mod Pathol. 2009 Sep;22(9):1133-8. (PMID: 19543244) Maturitas. 2010 Jul;66(3):310-4. (PMID: 20409655) JAMA. 2010 Sep 1;304(9):967-75. (PMID: 20810374) Am J Surg Pathol. 2010 Oct;34(10):1407-16. (PMID: 20861711) Am J Obstet Gynecol. 2011 Jan;204(1):19.e1-6. (PMID: 20619389) BJOG. 2011 Jun;118(7):814-24. (PMID: 21392246) Gynecol Oncol. 2011 Jun 1;121(3):472-6. (PMID: 21411127) Int J Gynecol Pathol. 2011 Sep;30(5):417-24. (PMID: 21804388) Lancet Oncol. 2011 Nov;12(12):1089-91. (PMID: 21868285) Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):134-47. (PMID: 22144499) J Pathol. 2012 Feb;226(3):421-6. (PMID: 21990067) JAMA. 2012 Jan 25;307(4):382-90. (PMID: 22274685) BJOG. 2012 Jun;119(7):810-6. (PMID: 22531019) Gynecol Oncol. 2012 Oct;127(1):88-93. (PMID: 22710074) Cancer Prev Res (Phila). 2012 Nov;5(11):1291-7. (PMID: 23009828) Obstet Gynecol. 2013 Jan;121(1):14-24. (PMID: 23232752) Mod Pathol. 2013 Apr;26(4):572-8. (PMID: 23080033) J Natl Cancer Inst. 2013 Jun 5;105(11):812-22. (PMID: 23628597) Ann Oncol. 2013 Aug;24(8):2036-42. (PMID: 23543211) Ann Oncol. 2013 Nov;24 Suppl 8:viii28-viii35. (PMID: 24131966) Int J Gynecol Cancer. 2013 Nov;23(9):1603-11. (PMID: 24172097) Am J Obstet Gynecol. 2013 Nov;209(5):409-14. (PMID: 23583217) Arch Gynecol Obstet. 2014 Feb;289(2):241-6. (PMID: 24100801) Gynecol Oncol. 2014 May;133(2):283-6. (PMID: 24582866) J Clin Oncol. 2014 May 20;32(15):1547-53. (PMID: 24567435) Crit Rev Oncol Hematol. 2014 Aug;91(2):159-71. (PMID: 24529552) Gynecol Oncol. 2014 Sep;134(3):492-7. (PMID: 25026639) Gynecol Oncol. 2015 Feb;136(2):305-10. (PMID: 25560807) J Natl Cancer Inst. 2015 May;107(5). pii: djv033. doi: 10.1093/jnci/djv033. (PMID: 25788320) J Sex Marital Ther. 2000 Apr-Jun;26(2):191-208. (PMID: 10782451) Maturitas. 2001 Apr 20;38(2):123-8. (PMID: 11306200) J Pathol. 2001 Nov;195(4):451-6. (PMID: 11745677) N Engl J Med. 2002 May 23;346(21):1609-15. (PMID: 12023992) N Engl J Med. 2002 May 23;346(21):1616-22. (PMID: 12023993) J Sex Marital Ther. 2002 Jul-Sep;28(4):317-30. (PMID: 12082670) Am J Hum Genet. 2003 May;72(5):1117-30. (PMID: 12677558) Gynecol Oncol. 2003 Aug;90(2):491. (PMID: 12893227) Med Decis Making. 2003 Jul-Aug;23(4):281-92. (PMID: 12926578) Int J Gynecol Pathol. 2004 Jan;23(1):35-40. (PMID: 14668548) Am J Obstet Gynecol. 2004 Oct;191(4):1113-23. (PMID: 15507929) Health Policy. 1990 Dec;16(3):199-208. (PMID: 10109801) Med Care. 1992 Jun;30(6):473-83. (PMID: 1593914) J Clin Oncol. 1994 Apr;12(4):843-50. (PMID: 8151327) Med Decis Making. 1995 Jan-Mar;15(1):25-30. (PMID: 7898294) Eur J Cancer. 2005 Mar;41(4):549-54. (PMID: 15737559) J Med Genet. 1998 Sep;35(9):731-8. (PMID: 9733031) Maturitas. 1998 May 20;29(1):25-31. (PMID: 9643514) Gynecol Oncol. 2005 May;97(2):476-82. (PMID: 15863147) Br J Cancer. 2006 Mar 27;94(6):814-9. (PMID: 16495917) |
| سلسلة جزيئية: | ClinicalTrials.gov NCT02321228 |
| المشرفين على المادة: | 0 (BRCA1 Protein) 0 (BRCA1 protein, human) 0 (BRCA2 Protein) 0 (BRCA2 protein, human) |
| تواريخ الأحداث: | Date Created: 20150820 Date Completed: 20160602 Latest Revision: 20181113 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC4541725 |
| DOI: | 10.1186/s12885-015-1597-y |
| PMID: | 26286255 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder كن أول من يترك تعليقا!